[{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Undisclosed","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"BTIG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ BTIG","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ BTIG"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Fenway Sports Group","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Fenway Sports Group"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Great Point Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Great Point Partners","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Great Point Partners"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Affinity Asset Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Affinity Asset Advisors","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Affinity Asset Advisors"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Fenway Sports Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Financing","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Fenway Sports Group","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Fenway Sports Group"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Leede Jones Gable","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Leede Jones Gable","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Leede Jones Gable"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Public Offering","leadProduct":"PMN310","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PMN400","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"ProMIS Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"ProMIS Neurosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProMIS Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"ProMIS Neurosciences \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by ProMIS Neurosciences
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
